Abstract:Background Liver targeting drug delivery systems can improve the curative effects and relieve the cytotoxicity of the chemotherapy drugs in the treatment of liver diseases. Nanoparticles carrying therapeutic drugs are currently under hot investigation with great clinical significance. This study was aimed to investigate the different tissue distribution of the adriamycin polybutylcyanoacrylate nanoparticle (ADM-PBCA-NP) in the mice body after an injection via lateral tail vein, and to study the liver targeting effects of ADM-PBCA-NP in different diameters on normal mice liver.Methods One hundred and eighty Kunming mice were randomly divided into 6 groups with 30 mice in each group (5 treatment groups of ADM-PBCA-NP in the different diameter ranges, non-conjugated free adriamycin injection was employed as the control group). A single dose of either conjugated or free adriamycin equaled 2 mg/kg of body weight was delivered via the tail vein. Five mice in each trail were sacrificed at 5, 15, 30 minutes, 1, 5 and 12 hours postinjection, respectively. The adriamycin concentrations in the respectively collected liver, kidney, spleen, heart, lung and plasma were demonstrated using a high performance liquid chromatography with fluorescence detector.Results Compared with the control group, adriamycin was hardly detected in the heart muscle of the treatment groups (P < 0.05). The nanoparticle-conjugated adriamycin was cleaned up quickly from the kidney tissue. The adriamycin concentrations of the mice liver and spleen in the experimental groups were significantly higher than that in the control group, except for the group with the nanoparticles diameters of (22.3 +/- 6.2) nm (P < 0.05). The ADM-PBCA-NP in (101.0 +/- 20.3) nm diameter had the highest liver distribution, and the second highest adriamycin distribution in liver was the group of (143.0 +/- 23.5) nm diameter (P < 0.05). Moreover, adriamycin was released slowly in the liver during the detection period in the experimental groups. ADM-PBCA-NP in (22.3 +/- 6.2) nm diameter was not distributed in the tissue of the liver, kidney, heart, spleen, and lung.Conclusions ADM-PBCA-NP in 100-150 nm diameter range has the best liver targeting with a characteristic of slow medicine release. It also decreases the medicine distribution in the heart, kidney and lung. In the treatment of liver cancer, the polybutylcyanoacrylate, nanoparticles system has a good liver targeting ability, which increases the anticancer activity and markedly decreases the toxicity of adriamycin.

Tissue Distribution of Cisplatin-Loaded Magnetic Nanomedicine in Mice

Preventive Effect of Meglumine on Rat's Nephrotoxicity Induced by Cisplatin and Discussion on Its Mechanism

Biodistribution of Cisplatinloaded Magnetic Iron Oxide Nanoparticles in Nude Mice Bearing Human Head and Neck Cancer

Effect of Alarelin Combined with Cisplatin on Subcutaneous Xenograft of Human Endometrial Carcinoma in Nude Mice

Pharmacokinetics of Cisplatin Packaged in a Nanometer Liposome

Liver Targeting and the Delayed Drug Release of the Nanoparticles of Adriamycin Polybutylcyanoacrylate in Mice

Distribution of Magnetic Aclacinomycin-A Nanoparticles in Mice

[Lethal Effects of Nanoliposome Encapsulated Cisplatin on Saos-2 Cells and Its Distribution in Nude Mice Bearing Human].

In Vivo Assessment of Hepatotoxicity, Nephrotoxicity and Biodistribution Using 3-Aminopropyltriethoxysilane-coated Magnetic Nanoparticles (Apts-Mnps) in ICR Mice

Anticancer effect of long-circulating nanometer liposome packaging cisplatin in vitro and in vivo

Acute toxicity study of cisplatin loaded polylactic acid-polyethylene glycol nanoparticles for targeting oral carcinoma

^188 Re Labeled MPEG-modified Superparamagnetic Nanogels：preparation and Preliminary Application in Mice

Superior Antitumor Efficiency of Cisplatin-Loaded Nanoparticles by Intratumoral Delivery with Decreased Tumor Metabolism Rate

The Concentration Changes of Lobaplatin and Cisplatin Injected Intravenously in Mice Bearing Lewis Lung Carcinoma

Distribution and Clearance of PEG-single-walled Carbon Nanotube Cancer Drug Delivery Vehicles in Mice

Tissue Distribution of Doxorubicin-Loaded Nanoparticles Based on Cholesterol-Modified Glycol Chitosan in S180-Bearing Mice

Determination of CS-PAA-EPI Polymer Magnetic Nanopaticle in Mouse Plasma

Comparison Between Different Modified Magnetic Nanoparticles in Biosafety

Local Therapeutic Effect of Tetrandrine and Cisplatin on Hepatocellular Carcinoma in Mice

Tissue Distribution, Histopathological and Genotoxic Effects of Magnetite Nanoparticles on Ehrlich Solid Carcinoma

Potential health impact on mice after nasal instillation of nano-sized copper particles and their translocation in mice.